PFS Cancer Research Results

PFS, progression-free survival: Click to Expand ⟱
Source:
Type:

PFS (progression-free survival) is the time from a defined starting point—usually randomization or treatment initiation—until documented disease progression or death, whichever occurs first
Scientific Papers found: Click to Expand⟱
7708- ,  lpi,    Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial
- Trial, CRC, NA
PFS↑,
7482- H2,    Molecular Hydrogen Therapy: Mechanisms, Delivery Methods, Preventive, and Therapeutic Application
- Review, Var, NA - Review, IBD, NA - Review, Stroke, NA - Review, Sepsis, NA - Review, AD, NA
Dose↝, *Inflam↓, *IL1β↓, *IL6↓, *TNF-α↓, *neuroP↑, *mTOR↓, *IL10↑, *TGF-β↑, *Sepsis↓, *NRF2↑, *antiOx↑, *Catalase↑, *SOD↑, *GPx↑, *ROS↓, *HO-1↑, *PI3K↑, *Akt↑, *hepatoP↑, *MPO↓, *cardioP↑, CDK4↓, CDK6↑, CD47↓, PI3K↓, Akt↓, Hif1a↓, selectivity↑, *MMP↑, *ATP↑, *ER Stress↓, *CHOP/DDIT3↓, *Casp12↓, *GRP78/BiP↓, *p38↓, *p‑JNK↓, *LC3‑Ⅱ/LC3‑Ⅰ↑, *p‑eIF2α↓, *ATF4↓, *XBP-1↓, *Imm↑, *IFN-γ↓, *IL4↓, *GranB/GZMB↓, NK cell↑, radioP↑, *CD4+↑, CD8+↑, *Dose↝, *other↑, *Dose↝, *antiPs↑, *BioAv↝, *GutMicro↑, Dose↝, *IBI↑, TumCP↓, TumCI↓, TumCMig↓, CD8+↑, PGC-1α↑, Akt↓, SCD1↓, *MDA↓, eff↑, *APP↓, *BACE/β-secretase↓, *Aβ↓, *cognitive↑, *neuroP↑, NP/CIPN↓, *Stroke↓, *NLRP3↓, *ALAT↓, *AST↓, *LPS↓, *hepatoP↑, chemoP↑, *creat↓, *Urea↓, *RenoP↑, *eff↑, Apoptosis↑, XIAP↓, IAP2/BIRC3↓, TumVol↓, MALAT1↓, EZH2↓, miR-124-3p↓, eff↑, ChemoSen↑, *compII↑, *compIII↑, *LDL↓, *Obesity↓, QoL↑, PFS↑,
7990- itraC,    A Novel Approach to Reducing Chemoresistance in Advanced Ovarian Cancer: The Effect of Itraconazole-A Single-Institution Randomized Placebo-Controlled Trial
- Trial, Ovarian, NA
Dose↝, DCR↑, PFS↑, CA125↓, P-gp/ABCB1↓, VEGFR2/KDR/Flk1↑, toxicity↓, QoL↑, toxicity↝,
8018- itraC,  Chemo,    Impact of combination chemotherapy with itraconazole on survival of patients with refractory ovarian cancer
- Trial, Ovarian, NA
PFS↑, OS↑, other↝,
8126- LF,    Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy
- NA, NSCLC, NA
Dose↝, OS↑, PFS↑, DCR↑, other↝,
8128- LF,    Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma
- Trial, RCC, NA
Imm↑, NK cell↑, Dose↝, toxicity↓, PFS↑,

Showing Research Papers: 1 to 6 of 6

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 6

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

CD47↓, 1,   DCR↑, 2,   miR-124-3p↓, 1,   PFS↑, 6,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

PGC-1α↑, 1,   XIAP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

SCD1↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 2,   Apoptosis↑, 1,   IAP2/BIRC3↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

EZH2↓, 1,   other↝, 2,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK4↓, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

PI3K↓, 1,  

Migration(tgid=13) ⓘ

MALAT1↓, 1,   TumCI↓, 1,   TumCMig↓, 1,   TumCP↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

Hif1a↓, 1,   VEGFR2/KDR/Flk1↑, 1,  

Barriers & Transport(tgid=15) ⓘ

P-gp/ABCB1↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Imm↑, 1,   NK cell↑, 2,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

CDK6↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

ChemoSen↑, 1,   Dose↝, 5,   eff↑, 2,   selectivity↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

CA125↓, 1,   EZH2↓, 1,  

Functional Outcomes(tgid=23) ⓘ

chemoP↑, 1,   NP/CIPN↓, 1,   OS↑, 2,   QoL↑, 2,   radioP↑, 1,   toxicity↓, 2,   toxicity↝, 1,   TumVol↓, 1,  

Infection & Microbiome(tgid=24) ⓘ

CD8+↑, 2,  
Total Targets: 39

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

compII↑, 1,   Stroke↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   Catalase↑, 1,   GPx↑, 1,   HO-1↑, 1,   MDA↓, 1,   MPO↓, 1,   NRF2↑, 1,   ROS↓, 1,   SOD↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↑, 1,   compIII↑, 1,   MMP↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 1,   LDL↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↑, 1,   Casp12↓, 1,   GranB/GZMB↓, 1,   p‑JNK↓, 1,   p38↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

other↑, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↓, 1,   p‑eIF2α↓, 1,   ER Stress↓, 1,   GRP78/BiP↓, 1,   XBP-1↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

LC3‑Ⅱ/LC3‑Ⅰ↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

mTOR↓, 1,   PI3K↑, 1,  

Migration(tgid=13) ⓘ

APP↓, 1,   TGF-β↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

ATF4↓, 1,  

Barriers & Transport(tgid=15) ⓘ

IBI↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD4+↑, 1,   IFN-γ↓, 1,   IL10↑, 1,   IL1β↓, 1,   IL4↓, 1,   IL6↓, 1,   Imm↑, 1,   Inflam↓, 1,   LPS↓, 1,   TNF-α↓, 1,  

Protein Aggregation(tgid=19) ⓘ

Aβ↓, 1,   BACE/β-secretase↓, 1,   NLRP3↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↝, 1,   Dose↝, 2,   eff↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   AST↓, 1,   creat↓, 1,   GutMicro↑, 1,   IL6↓, 1,   Urea↓, 1,  

Functional Outcomes(tgid=23) ⓘ

antiPs↑, 1,   cardioP↑, 1,   cognitive↑, 1,   hepatoP↑, 2,   neuroP↑, 2,   Obesity↓, 1,   RenoP↑, 1,  

Infection & Microbiome(tgid=24) ⓘ

Sepsis↓, 1,  
Total Targets: 64

Scientific Paper Hit Count for: PFS, progression-free survival
2 itraconazole
2 Lactoferrin/Talactoferrin
1 ipilimumab
1 Hydrogen Gas
1 Chemotherapy
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1559  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page